

## AMENDMENTS TO THE CLAIMS

Please cancel claims 1-11 without prejudice.

Please add claims 12-27.

The following is a complete listing of the claims:

Claims 1-11 (canceled without prejudice).

Claim 12 (new). A stable enteric coated pellet consisting essentially of :

- a) a core consisting essentially of 10-50 weight percent based on the total weight of the core of omeprazole or a pharmaceutically acceptable salt thereof, a surface active agent, a filler, a binder and 0.5 to 10 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine; and
- b) a coating layer surrounding the core that consists essentially of an enteric coating agent, 5 to 50 weight percent based on the total weight of the coating layer of an inert processing aid and optionally a plasticizer wherein the enteric coating layer is applied directly to the omeprazole containing core without a separating layer between the omeprazole containing core and enteric coating layer.

Claim 13 (new). The pellet as recited in claim 12 wherein the core consists essentially of 10 to 50 weight percent based on the total weight of the core of omeprazole, a surface active agent, a filler, a binder and 0.5 to 10 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine.

Claim 14 (new). The pellet as recited in claim 12 wherein the core consists essentially of 10 to 50 weight percent based on the total weight of the core of a pharmaceutically acceptable salt of omeprazole, a surface active agent, a filler, a binder and 0.5 to 10 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine.

Claim 15 (new). The pellet as recited in claim 12 wherein the plasticizer in the enteric coating is not optional.

Claim 16 (new). The pellet as recited in claim 12 wherein the enteric coating agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethyl cellulose, copolymerized methacrylic acid/methacrylic acid methyl esters.

Claim 17 (new). The pellet as recited in claim 12 wherein the inert processing aid is selected from the group consisting of talc, silicon dioxide and magnesium stearate.

Claim 18 (new). The pellet as recited in claim 12 wherein the core consists essentially of 10 to 50 weight percent based on the total weight of the core of omeprazole, 0.20 to 2.0 weight percent based upon the total weight of the core of a surface active agent, 20 to 90 weight percent based on the total weight of the core of a filler, 0.1 to 10 weight percent based on the total weight of the core of a binder and 1 to 3 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine.

Claim 19 (new). The pellet as recited in claim 12 wherein the core consists essentially of 10 to 50 weight percent based on the total weight of the core of a pharmaceutically acceptable salt of omeprazole, 0.20 to 2.0 weight percent based upon the total weight of the core of a surface active agent, 20 to 90 weight percent based on the total weight of the core of a filler, 0.1 to 10 weight percent based on the total weight of the core of a binder and 1 to 3 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine.

Claim 20 (new). A stable enteric coated pellet consisting essentially of :

(a) a core consisting essentially of: (a) an inert core and (b) a drug layer consisting essentially of 10-50 weight percent based on the total weight of the core of omeprazole or a pharmaceutically acceptable salt, a surface active agent, a filler, a binder and 0.5 to 10 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine; and

(b) a coating layer surrounding the core that consists essentially of an enteric coating agent, 5 to 50 weight percent based on the total weight of the coating layer of an inert processing aid and optionally a plasticizer wherein the enteric coating layer is applied directly to the omeprazole containing core without a separating layer between the omeprazole containing core and enteric coating layer.

Claim 21 (new). The pellet as recited in claim 20 wherein the drug layer consists essentially of 10 to 50 weight percent based on the total weight of the core of

omeprazole, a surface active agent, a filler, a binder and 0.5 to 10 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine.

Claim 22 (new). The pellet as recited in claim 20 wherein the drug layer consists essentially of 10 to 50 weight percent based on the total weight of the core of a pharmaceutically acceptable salt of omeprazole, a surface active agent, a filler, a binder and 0.5 to 10 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine.

Claim 23 (new). The pellet as recited in claim 20 wherein the plasticizer in the enteric coating is not optional.

Claim 24 (new). The pellet as recited in claim 20 wherein the enteric coating agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethyl cellulose, copolymerized methacrylic acid/methacrylic acid methyl esters.

Claim 25 (new). The pellet as recited in claim 20 wherein the inert processing aid is selected from the group consisting of talc, silicon dioxide and magnesium stearate.

Claim 26 (new). The pellet as recited in claim 20 wherein the drug layer consists essentially of 10 to 50 weight percent based on the total weight of the core of omeprazole, 0.20 to 2.0 weight percent based upon the total weight of the core of a surface active agent, 20 to 90 weight percent based on the total weight of the core of a filler, 0.1 to 10 weight percent based on the total weight of the core of a binder and 1 to 3 weight percent

based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine.

Claim 27 (new). The pellet as recited in claim 20 wherein the drug layer consists essentially of 10 to 50 weight percent based on the total weight of the core of a pharmaceutically acceptable salt of omeprazole, 0.20 to 2.0 weight percent based upon the total weight of the core of a surface active agent, 20 to 90 weight percent based on the total weight of the core of a filler, 0.1 to 10 weight percent based on the total weight of the core of a binder and 1 to 3 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine.